NewLimit Secures $130 Million to Drive Age-Reversal Research

Biotech firm NewLimit, co-founded by Coinbase CEO Brian Armstrong, has secured a significant $130 million in funding through a Series B round. This investment from Kleiner Perkins will accelerate its research into age-reversing therapies, placing the company at the forefront of this growing field. While early trials are expected to be years away, experts foresee substantial health benefits and potential for extended lifespans.